The global ischemic heart disease (IHD) drugs market is expected to exhibit strong growth during 2021-2026. Ischemic heart disease (IHD), also known as coronary heart disease, is a condition that damages the heart muscle by interrupting the oxygen and blood supply. It involves molecular changes in the blood vessels or sudden closure and narrowing of coronary arteries by atheroma. The disease is often characterized by chronic chest pain and severe discomfort and can be fatal if left untreated. Various drugs are used to treat IHD depending on the intensity of the case. For instance, if cholesterol-modifying medication decreases cholesterol levels in the blood, then aspirin is prescribed to reduce clotting tendencies of the blood, and beta blockers are utilized to lower the heart rate and decrease blood pressure. IHD drugs also include calcium channel blockers and ranolazine that improve the efficiency of beta blockers and prevent further progression of coronary disease.
The growing inclination of the masses towards interventional medical procedures along with extensive utilization of anti-anginal medications for the treatment of IHD is one of the key factors driving the market growth. IHD drugs are being incorporated in cardiological treatment procedures such as angioplasty, atherectomy and balloon angioplasty to ensure a healthy recovery and prevent relapse in the future. Additionally, rising consumer awareness regarding the benefits of scheduled administration of these drugs is also creating a significant impact on their demand. Lifestyle habits such as excessive alcohol consumption and smoking along with physical inactiveness are also leading to an increasing prevalence of cardiovascular diseases. Furthermore, the expanding population of geriatrics around the globe, who are severely prone to heart ailments, is also boosting the demand for IHD drugs. Looking forward, IMARC Group expects the global ischemic heart disease (IHD) drugs market to grow at a CAGR of around 10% during the forecast period (2021-2026).
Market Breakup by Disease Class
Market Breakup by Drug Class:
Market Breakup by Region:
The competitive landscape of the industry has also been examined with some of the key players being Actelion, Amgen Inc., AstraZeneca plc, Bayer AG, Baxter International Inc., Boehringer Ingelheim, Bristol-Myers Squibb, Eisai Co. Ltd., Eli Lilly, F.Hoffmann-La Roche, GlaxoSmithKline, Merck, Novartis, Pfizer Inc., and Sanofi S.A.
Key Questions Answered in This Report:
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at